止血剤市場 : 2028年までの世界予測

Report Overview

The hemostats market is valued at an estimated USD 2.7 billion in 2023 and is projected to reach USD 3.7 billion by 2028 at a CAGR of 6.7% during the forecast period. The geriatric population represents a demographic segment with a rising demand for surgical procedures, thus underscoring the critical need for hemostatic agents in modern healthcare. Advancing age brings an increased susceptibility to a multitude of medical conditions and chronic diseases, often necessitating surgical interventions to sustain or enhance the overall quality of life. These surgical interventions span a wide spectrum, encompassing orthopedic joint replacements, intricate cardiac procedures, and complex gastrointestinal surgeries. Given the physiological transformations inherent to aging, including diminished tissue elasticity and heightened vulnerability to hemorrhages, the precise and efficient utilization of hemostatic agents assumes paramount significance in the surgical care of elderly patients. As the global geriatric population continues its steady expansion, the requirement for hemostats is anticipated to amplify proportionally, thus emphasizing their indispensable role in addressing the nuanced healthcare needs of elderly individuals undergoing surgical treatments.

“Combination hemostats segment accounted for the highest growth rate in the hemostats market, by type, during the forecast period.”
The hemostats market is bifurcated into oxidized regenerated cellulose-based hemostats, thrombin-based hemostats, combination hemostats, gelatin-based hemostats, collagen-based hemostats, and other hemostats on the basis of type. The combination hemostats segment in the hemostats market is experiencing substantial growth. Combination hemostats are often more effective at achieving hemostasis than single-agent hemostats. This is because they combine the strengths of different types of hemostats.

“Sponge hemostats segment accounted for the highest growth rate in the hemostats market, by formulation, during the forecast period.”
The global hemostats market is bifurcated into matrix & gel hemostats, sheet & pad hemostats, sponge hemostats, and powder hemostats. The sponge hemostats segment is currently witnessing the highest growth rate within the hemostats market. Market growth can largely be attributed to the growing acceptance of these formulations by end users due to the various advantages associated with them.

“Asia Pacific: The fastest-growing region hemostats market”
The global hemostats market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to witness the highest growth during the forecast period. Emerging countries in this region are witnessing growth in their GDPs and a significant rise in disposable income levels. This has led to increased healthcare spending by a larger population base. Other factors such as the increasing incidence & prevalence of chronic diseases, increasing burden of surgical procedures, healthcare infrastructure modernization, and the rising penetration of cutting-edge technologies (especially in rural areas) in Asia Pacific countries are also expected to provide significant growth opportunities for hemostats companies in this region. Also, other factors contributing to the growth include government efforts to increase awareness about the management of diseases and the increasing number of hospitals and clinics in India and China. The healthcare expenditure in Asian countries has also increased drastically. Growth in healthcare expenditure serves to increase the purchasing power of healthcare providers and stimulate the adoption of advanced medical/surgical supplies, including hemostats, in the region.

The break-up of the profile of primary participants in the hemostats market:
• By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier 3 – 30%
• By Designation: C-level – 27%, D-level – 18%, and Others – 55%
• By Region: North America – 51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and Middle East & Africa- 4%

The key players in this market are Johnson & Johnson (US), Baxter International (US), Pfizer Inc. (US), B. Braun SE (Germany), Becton, Dickinson and Company (US), Teleflex Incorporated (US), Medtronic Plc (Ireland), Hemostasis, LLC (US), Stryker Corporation (US), Integra LifeSciences (US), Advanced Medical Solutions Group Plc (UK), Samyang Holdings Corporation (South Korea), Marine Polymer Technologies, Inc. (US), GELITA MEDICAL GmbH (Germany), Dilon Technologies, Inc. (US), Betatech Medical (Turkey), Meril Life Sciences Pvt. Ltd. (India), BioCer Entwicklungs-GmbH (Germany), Unilene (US), Katsan Medical Devices (Turkey), Tricol Biomedical (US), 3-D Matrix Medical Technology (Japan), Hemostat Medical GmbH (Germany), Medtrade Products Limited (UK), and Altaylar Medical (Turkey).

Research Coverage:
This research report categorizes the hemostats market by type (thrombin-based hemostats, oxidized regenerated cellulose-based hemostats, combination hemostats, gelatin-based hemostats, collagen-based hemostats, and other hemostats), formulation (orthopedic surgery, general surgery, neurological surgery, cardiovascular surgery, reconstructive surgery, and gynecological surgery, and other surgical applications), application (matrix & gel hemostats, sheet & pad hemostats, sponge hemostats, and powder hemostats), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the hemostats market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches and recent developments associated with the hemostats market. Competitive analysis of upcoming startups in the hemostats market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall hemostats market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:
• Analysis of key drivers (growing volume of surgical procedures performed, rising focus on R&D, and rising focus on effective blood loss management in patients during surgeries), restraints (side effects and allergic reactions associated with hemostats), opportunities (growth opportunities in emerging economies and growing number of hospitals), and challenges (stringent regulatory framework, dearth of skilled personnel for effective use of hemostats, and high cost of hemostats) influencing the growth of the hemostats market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the hemostats market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the hemostats market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the hemostats market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Johnson & Johnson (US), Baxter International (US), Pfizer Inc. (US), B. Braun SE (Germany), and Becton, Dickinson and Company (US), among others in the hemostats market strategies

Table of Contents

1            INTRODUCTION            21

1.1         STUDY OBJECTIVES      21

1.2         MARKET DEFINITION   21

1.2.1      INCLUSIONS & EXCLUSIONS     22

1.3         STUDY SCOPE  22

1.3.1      HEMOSTATS MARKET  22

1.3.2      GEOGRAPHIC SCOPE    23

1.3.3      YEARS CONSIDERED     23

1.4         CURRENCY        23

1.5         LIMITATIONS   24

1.6         STAKEHOLDERS            24

1.7         SUMMARY OF CHANGES            24

2            RESEARCH METHODOLOGY     26

2.1         RESEARCH DATA           26

2.2         RESEARCH APPROACH 26

FIGURE 1           HEMOSTATS MARKET: RESEARCH DESIGN METHODOLOGY              26

2.2.1      SECONDARY DATA       27

2.2.1.1   Key data from secondary sources     27

2.2.2      PRIMARY DATA 28

2.2.2.1   Primary sources   29

2.2.2.2   Key data from primary sources         29

2.2.2.3   Key industry insights          30

2.2.2.4   Breakdown of primary interviews     30

FIGURE 2           BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 30

FIGURE 3           BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION    31

2.3         MARKET SIZE ESTIMATION       31

2.3.1      BOTTOM-UP APPROACH           32

2.3.1.1   Approach 1: Company revenue estimation approach    32

FIGURE 4           BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH       32

2.3.1.2   Approach 2: Presentations of companies and primary interviews              32

2.3.1.3   Growth forecast   33

2.3.1.4   CAGR projections             33

FIGURE 5           CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS   33

2.3.2      TOP-DOWN APPROACH             33

FIGURE 6           HEMOSTATS MARKET: TOP-DOWN APPROACH 34

2.4         MARKET BREAKDOWN AND DATA TRIANGULATION    35

FIGURE 7           DATA TRIANGULATION METHODOLOGY         35

2.5         MARKET SHARE ANALYSIS         36

2.6         STUDY ASSUMPTIONS  36

2.7         GROWTH RATE ASSUMPTIONS 36

2.8         RISK ASSESSMENT         37

2.8.1      RISK ASSESSMENT: HEMOSTATS MARKET          37

2.9         RECESSION IMPACT      37

3            EXECUTIVE SUMMARY 39

FIGURE 8           HEMOSTATS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)              39

FIGURE 9           HEMOSTATS MARKET, BY FORMULATION, 2023 VS. 2028 (USD MILLION)          40

FIGURE 10         HEMOSTATS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)          40

FIGURE 11         HEMOSTATS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)          41

4            PREMIUM INSIGHTS      42

4.1         HEMOSTATS MARKET OVERVIEW          42

FIGURE 12         GROWING NEED TO MANAGE BLOOD LOSS IN PATIENTS DURING SURGICAL PROCEDURES TO DRIVE MARKET GROWTH            42

4.2         HEMOSTATS MARKET SHARE, BY TYPE, 2023 VS. 2028    42

FIGURE 13         OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS TO CONTINUE TO DOMINATE MARKET IN 2028             42

4.3         HEMOSTATS MARKET SHARE, BY FORMULATION, 2023 VS. 2028              43

FIGURE 14         MATRIX & GEL HEMOSTATS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 43

4.4         HEMOSTATS MARKET SHARE, BY APPLICATION, 2023 VS. 2028  43

FIGURE 15         ORTHOPEDIC SURGERY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD     43

4.5         HEMOSTATS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES              44

FIGURE 16         ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN HEMOSTATS MARKET DURING FORECAST PERIOD       44

5            MARKET OVERVIEW     45

5.1         INTRODUCTION            45

5.2         MARKET DYNAMICS     45

FIGURE 17         HEMOSTATS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    45

5.2.1      DRIVERS            46

5.2.1.1   Growing volume of surgical procedures performed      46

TABLE 1             TOTAL NUMBER OF KNEE REPLACEMENTS, 2021           47

TABLE 2             TOTAL NUMBER OF CORONARY ARTERY BYPASS GRAFT PROCEDURES, 2021       48

5.2.1.2   Rising focus on R&D          48

5.2.1.3   Rising focus on effective blood loss management in patients during surgeries              49

5.2.2      RESTRAINTS     49

5.2.2.1   Side effects and allergic reactions associated with hemostats      49

5.2.3      OPPORTUNITIES           50

5.2.3.1   Growth opportunities in emerging economies 50

TABLE 3             COST OF SURGICAL PROCEDURES: US VS. INDIA (USD) 50

5.2.3.2   Growing number of hospitals           51

5.2.4      CHALLENGES   51

5.2.4.1   Stringent regulatory framework       51

5.2.4.2   Dearth of skilled personnel for effective use of hemostats           52

5.2.4.3   High cost of hemostats       52

5.3         PRICING ANALYSIS        52

5.3.1      INDICATIVE PRICING MODEL ANALYSIS OF MARKET PLAYERS 52

TABLE 4             INDICATIVE PRICING FOR HEMOSTATS             52

5.3.2      AVERAGE SELLING PRICE OF HEMOSTATS, BY REGION 53

TABLE 5             AVERAGE SELLING PRICE OF HEMOSTATS        53

5.4         VALUE CHAIN ANALYSIS            53

FIGURE 18         VALUE CHAIN ANALYSIS OF HEMOSTATS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES     54

5.5         SUPPLY CHAIN ANALYSIS          55

FIGURE 19         HEMOSTATS MARKET: SUPPLY CHAIN ANALYSIS           55

5.6         PATENT ANALYSIS        56

FIGURE 20         PATENT ANALYSIS FOR HEMOSTATS (JANUARY 2013–DECEMBER 2022)           56

5.6.1      LIST OF MAJOR PATENTS          57

5.7         TRADE ANALYSIS          57

5.7.1      TRADE ANALYSIS FOR HEMOSTATS      57

TABLE 6             IMPORT DATA FOR HEMOSTATS, BY COUNTRY, 2018–2022 (USD MILLION) 57

TABLE 7             EXPORT DATA FOR HEMOSTATS, BY COUNTRY, 2018–2022 (USD MILLION) 58

5.8         ECOSYSTEM ANALYSIS 58

FIGURE 21         HEMOSTATS MARKET: ECOSYSTEM ANALYSIS  58

5.8.1      HEMOSTATS MARKET: ROLE IN ECOSYSTEM    59

5.9         PORTER’S FIVE FORCES ANALYSIS         59

TABLE 8             HEMOSTATS MARKET: PORTER’S FIVE FORCES ANALYSIS              59

5.9.1      THREAT OF NEW ENTRANTS    60

5.9.2      THREAT OF SUBSTITUTES         60

5.9.3      BARGAINING POWER OF SUPPLIERS     60

5.9.4      BARGAINING POWER OF BUYERS           60

5.9.5      INTENSITY OF COMPETITIVE RIVALRY 61

5.10       REGULATORY LANDSCAPE       61

TABLE 9             NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         61

TABLE 10           ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         62

TABLE 11           LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         62

TABLE 12           REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         62

5.10.1    NORTH AMERICA          63

5.10.1.1 US         63

TABLE 13           CLASSIFICATION OF MEDICAL DEVICES BY US FDA       63

FIGURE 22         PREMARKET NOTIFICATION: 510(K) APPROVAL FOR MEDICAL DEVICES            64

5.10.1.2 Canada  64

FIGURE 23         APPROVAL PROCESS FOR CLASS III MEDICAL DEVICES IN CANADA            64

5.10.2    EUROPE             65

FIGURE 24         CE APPROVAL PROCESS IN EUROPE FOR HEMOSTATS  65

5.10.3    ASIA PACIFIC    65

5.10.3.1 Japan     65

TABLE 14           CLASSIFICATION OF MEDICAL DEVICES AND REVIEWING BODY IN JAPAN 66

5.10.3.2 China     66

TABLE 15           NMPA MEDICAL DEVICES CLASSIFICATION       66

5.10.3.3 India      67

5.11       TECHNOLOGY ANALYSIS           67

5.12       TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 68

FIGURE 25         REVENUE SHIFT IN HEMOSTATS MARKET         68

6            HEMOSTATS MARKET, BY TYPE             69

6.1         INTRODUCTION            70

TABLE 16           HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)              70

TABLE 17           HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)              70

6.2         PRIMARY NOTES            71

6.2.1      KEY PRIMARY INSIGHTS             71

6.3         OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS     71

6.3.1      GROWING AVAILABILITY OF ORC-BASED HEMOSTATIC AGENTS ACROSS UNTAPPED MARKETS TO DRIVE GROWTH       71

TABLE 18           MAJOR PRODUCTS IN OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET   72

TABLE 19           OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION)            73

TABLE 20           OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION)            73

6.4         THROMBIN-BASED HEMOSTATS            73

6.4.1      DEVELOPMENTS IN RECOMBINANT THROMBIN PRODUCTS TO SUPPORT GROWTH      73

TABLE 21           MAJOR PRODUCTS IN THROMBIN-BASED HEMOSTATS MARKET            74

TABLE 22           THROMBIN-BASED HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION)     74

TABLE 23           THROMBIN-BASED HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION)     75

6.5         COMBINATION HEMOSTATS    75

6.5.1      ADVANCEMENTS IN COMBINATION MATERIALS TO PROPEL MARKET GROWTH          75

TABLE 24           MAJOR PRODUCTS IN COMBINATION HEMOSTATS MARKET              76

TABLE 25           COMBINATION HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION) 76

TABLE 26           COMBINATION HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION) 76

6.6         GELATIN-BASED HEMOSTATS  77

6.6.1      HIGH ELASTICITY OFFERED BY GELATIN-BASED HEMOSTATS TO BOOST DEMAND           77

TABLE 27           MAJOR PRODUCTS IN GELATIN-BASED HEMOSTATS MARKET              77

TABLE 28           GELATIN-BASED HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION) 77

TABLE 29           GELATIN-BASED HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION) 78

6.7         COLLAGEN-BASED HEMOSTATS            78

6.7.1      LOW COST AND REDUCED RISK OF DISEASE TRANSMISSION TO PROMOTE ADOPTION OF COLLAGEN-BASED HEMOSTATS       78

TABLE 30           MAJOR PRODUCTS IN COLLAGEN-BASED HEMOSTATS MARKET            79

TABLE 31           COLLAGEN-BASED HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION)     79

TABLE 32           COLLAGEN-BASED HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION)     79

6.8         OTHER HEMOSTATS    80

TABLE 33           OTHER HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION)          80

TABLE 34           OTHER HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION)          80

7            HEMOSTATS MARKET, BY FORMULATION         81

7.1         INTRODUCTION            82

TABLE 35           HEMOSTATS MARKET, BY FORMULATION, 2018–2021 (USD MILLION)          82

TABLE 36           HEMOSTATS MARKET, BY FORMULATION, 2022–2028 (USD MILLION)          82

7.2         MATRIX & GEL HEMOSTATS     83

7.2.1      ABILITY OF MATRIX & GEL HEMOSTATS TO ENHANCE PLATELET AGGREGATION TO BOOST MARKET     83

TABLE 37           MATRIX & GEL HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION) 83

TABLE 38           MATRIX & GEL HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION) 83

7.3         SHEET & PAD HEMOSTATS        84

7.3.1      ABILITY TO CUT SHEET & PAD HEMOSTATS INTO ANY SHAPE OR SIZE TO FUEL ADOPTION     84

TABLE 39           SHEET & PAD HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION) 84

TABLE 40           SHEET & PAD HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION) 84

7.4         SPONGE HEMOSTATS  85

7.4.1      GROWING ACCEPTANCE OF SPONGE HEMOSTATS TO FUEL UPTAKE              85

TABLE 41           SPONGE HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION)          85

TABLE 42           SPONGE HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION)          85

7.5         POWDER HEMOSTATS 86

7.5.1      ABILITY TO SPRAY POWDER FORMULATIONS DIRECTLY ON WOUNDS TO FUEL DEMAND        86

TABLE 43           POWDER HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION)          86

TABLE 44           POWDER HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION)          87

8            HEMOSTATS MARKET, BY APPLICATION           88

8.1         INTRODUCTION            89

TABLE 45           HEMOSTATS MARKET, BY APPLICATION, 2018–2021 (USD MILLION)          89

TABLE 46           HEMOSTATS MARKET, BY APPLICATION, 2022–2028 (USD MILLION)          89

8.2         PRIMARY NOTES            90

8.2.1      KEY PRIMARY INSIGHTS             90

8.3         ORTHOPEDIC SURGERY            90

8.3.1      INCREASING INCIDENCE OF SPORTS INJURIES TO SUPPORT MARKET GROWTH          90

TABLE 47           NUMBER OF KNEE & HIP REPLACEMENTS, 2021 91

TABLE 48           HEMOSTATS MARKET FOR ORTHOPEDIC SURGERY, BY REGION, 2018–2021 (USD MILLION)       91

TABLE 49           HEMOSTATS MARKET FOR ORTHOPEDIC SURGERY, BY REGION, 2022–2028 (USD MILLION)       92

8.4         GENERAL SURGERY      92

8.4.1      INCREASING NUMBER OF HERNIA REPAIR PROCEDURES TO DRIVE GROWTH          92

TABLE 50           TOTAL NUMBER OF INGUINAL HERNIA REPAIR PROCEDURES, 2021      93

TABLE 51           HEMOSTATS MARKET FOR GENERAL SURGERY, BY REGION, 2018–2021 (USD MILLION)          93

TABLE 52           HEMOSTATS MARKET FOR GENERAL SURGERY, BY REGION, 2022–2028 (USD MILLION)          93

8.5         NEUROLOGICAL SURGERY        94

8.5.1      GROWING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH        94

TABLE 53           HEMOSTATS MARKET FOR NEUROLOGICAL SURGERY, BY REGION, 2018–2021 (USD MILLION)       94

TABLE 54           HEMOSTATS MARKET FOR NEUROLOGICAL SURGERY, BY REGION, 2022–2028 (USD MILLION)       94

8.6         CARDIOVASCULAR SURGERY    95

8.6.1      RISING PREVALENCE OF CVD TO DRIVE ADOPTION OF HEMOSTATS              95

TABLE 55           HEMOSTATS MARKET FOR CARDIOVASCULAR SURGERY, BY REGION, 2018–2021 (USD MILLION)       95

TABLE 56           HEMOSTATS MARKET FOR CARDIOVASCULAR SURGERY, BY REGION, 2022–2028 (USD MILLION)       96

8.7         RECONSTRUCTIVE SURGERY    96

8.7.1      GROWING NUMBER OF COSMETIC SURGERIES TO SUPPORT MARKET GROWTH          96

TABLE 57           HEMOSTATS MARKET FOR RECONSTRUCTIVE SURGERY, BY REGION, 2018–2021 (USD MILLION)       97

TABLE 58           HEMOSTATS MARKET FOR RECONSTRUCTIVE SURGERY, BY REGION, 2022–2028 (USD MILLION)       97

8.8         GYNECOLOGICAL SURGERY     97

8.8.1      GROWING USE OF HEMOSTATS IN C-SECTION PROCEDURES TO CONTROL SURGICAL BLEEDING TO SUPPORT GROWTH           97

TABLE 59           HEMOSTATS MARKET FOR GYNECOLOGICAL SURGERY, BY REGION, 2018–2021 (USD MILLION)       98

TABLE 60           HEMOSTATS MARKET FOR GYNECOLOGICAL SURGERY, BY REGION, 2022–2028 (USD MILLION)       98

8.9         OTHER SURGICAL APPLICATIONS         99

TABLE 61           HEMOSTATS MARKET FOR OTHER SURGICAL APPLICATIONS, BY REGION, 2018–2021 (USD MILLION)  99

TABLE 62           HEMOSTATS MARKET FOR OTHER SURGICAL APPLICATIONS, BY REGION, 2022–2028 (USD MILLION)  100

9            HEMOSTATS MARKET, BY REGION        101

9.1         INTRODUCTION            102

TABLE 63           HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION)              102

TABLE 64           HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION)              102

9.2         NORTH AMERICA          103

FIGURE 26         NORTH AMERICA: HEMOSTATS MARKET SNAPSHOT    104

TABLE 65           NORTH AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2018–2021 (USD MILLION)     104

TABLE 66           NORTH AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2022–2028 (USD MILLION)     105

TABLE 67           NORTH AMERICA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 105

TABLE 68           NORTH AMERICA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 105

TABLE 69           NORTH AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2018–2021 (USD MILLION)          106

TABLE 70           NORTH AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2022–2028 (USD MILLION)          106

TABLE 71           NORTH AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2018–2021 (USD MILLION)          106

TABLE 72           NORTH AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2022–2028 (USD MILLION)          107

9.2.1      NORTH AMERICA: RECESSION IMPACT 107

9.2.2      US         107

9.2.2.1   Strong healthcare infrastructure to support uptake of hemostats 107

TABLE 73           US: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)              108

TABLE 74           US: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)              109

9.2.3      CANADA            109

9.2.3.1   Growing geriatric population and increasing volume of surgeries to drive demand for hemostats       109

TABLE 75           SURGICAL PROCEDURES PERFORMED IN CANADA, 2021              110

TABLE 76           CANADA: KEY MACROINDICATORS       110

TABLE 77           CANADA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)          110

TABLE 78           CANADA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)          111

9.3         EUROPE             111

TABLE 79           EUROPE: HEMOSTATS MARKET, BY COUNTRY, 2018–2021 (USD MILLION)          112

TABLE 80           EUROPE: HEMOSTATS MARKET, BY COUNTRY, 2022–2028 (USD MILLION)          112

TABLE 81           EUROPE: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)          113

TABLE 82           EUROPE: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)          113

TABLE 83           EUROPE: HEMOSTATS MARKET, BY FORMULATION, 2018–2021 (USD MILLION) 113

TABLE 84           EUROPE: HEMOSTATS MARKET, BY FORMULATION, 2022–2028 (USD MILLION) 114

TABLE 85           EUROPE: HEMOSTATS MARKET, BY APPLICATION, 2018–2021 (USD MILLION) 114

TABLE 86           EUROPE: HEMOSTATS MARKET, BY APPLICATION, 2022–2028 (USD MILLION) 114

9.3.1      EUROPE: RECESSION IMPACT   115

9.3.2      GERMANY         115

9.3.2.1   High healthcare expenditure in Germany to favor market growth             115

TABLE 87           SURGICAL PROCEDURES PERFORMED IN GERMANY, 2021              116

TABLE 88           GERMANY: KEY MACROINDICATORS    116

TABLE 89           GERMANY: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)          116

TABLE 90           GERMANY: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)          117

9.3.3      UK         117

9.3.3.1   Growing volume of hernia repair and cardiovascular surgeries to drive market growth   117

TABLE 91           SURGICAL PROCEDURES PERFORMED IN UK, 2021         118

TABLE 92           UK: KEY MACROINDICATORS   118

TABLE 93           UK: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)              118

TABLE 94           UK: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)              119

9.3.4      FRANCE             119

9.3.4.1   Presence of well-established healthcare system to propel market growth  119

TABLE 95           SURGICAL PROCEDURES PERFORMED IN FRANCE, 2021              120

TABLE 96           FRANCE: KEY MACROINDICATORS        120

TABLE 97           FRANCE: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)          120

TABLE 98           FRANCE: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)          121

9.3.5      ITALY   121

9.3.5.1   Increasing volume of surgeries to drive demand for hemostats   121

TABLE 99           SURGICAL PROCEDURES PERFORMED IN ITALY, 2021   122

TABLE 100         ITALY: KEY MACROINDICATORS            122

TABLE 101         ITALY: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)          122

TABLE 102         ITALY: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)          123

9.3.6      SPAIN   123

9.3.6.1   Growing healthcare budget and rising efforts to boost local manufacturing of medical products to drive market growth        123

TABLE 103         SURGICAL PROCEDURES PERFORMED IN SPAIN, 2021   124

TABLE 104         SPAIN: KEY MACROINDICATORS            124

TABLE 105         SPAIN: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)          124

TABLE 106         SPAIN: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)          125

9.3.7      RUSSIA 125

9.3.7.1   Long-term healthcare investment initiatives by government to support market growth   125

TABLE 107         RUSSIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)          126

TABLE 108         RUSSIA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)          126

9.3.8      SWITZERLAND 127

9.3.8.1   Increasing public health insurance coverage to drive number of surgical procedures           127

TABLE 109         SURGICAL PROCEDURES PERFORMED IN SWITZERLAND, 2021              127

TABLE 110         SWITZERLAND: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 127

TABLE 111         SWITZERLAND: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 128

9.3.9      BELGIUM          128

9.3.9.1   Increasing demand for value-based healthcare services to drive market growth              128

TABLE 112         SURGICAL PROCEDURES PERFORMED IN BELGIUM, 2021              128

TABLE 113         BELGIUM: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)          129

TABLE 114         BELGIUM: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)          129

9.3.10    REST OF EUROPE           129

TABLE 115         REST OF EUROPE: PERCENTAGE OF GDP ON HEALTHCARE EXPENDITURE, BY COUNTRY    130

TABLE 116         REST OF EUROPE: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 130

TABLE 117         REST OF EUROPE: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 130

9.4         ASIA PACIFIC    131

FIGURE 27         ASIA PACIFIC: HEMOSTATS MARKET SNAPSHOT            132

TABLE 118         ASIA PACIFIC: HEMOSTATS MARKET, BY COUNTRY, 2018–2021 (USD MILLION) 133

TABLE 119         ASIA PACIFIC: HEMOSTATS MARKET, BY COUNTRY, 2022–2028 (USD MILLION) 133

TABLE 120         ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)          134

TABLE 121         ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)          134

TABLE 122         ASIA PACIFIC: HEMOSTATS MARKET, BY FORMULATION, 2018–2021 (USD MILLION)     134

TABLE 123         ASIA PACIFIC: HEMOSTATS MARKET, BY FORMULATION, 2022–2028 (USD MILLION)     135

TABLE 124         ASIA PACIFIC: HEMOSTATS MARKET, BY APPLICATION, 2018–2021 (USD MILLION)     135

TABLE 125         ASIA PACIFIC: HEMOSTATS MARKET, BY APPLICATION, 2022–2028 (USD MILLION)     135

9.4.1      ASIA PACIFIC: RECESSION IMPACT        136

9.4.2      CHINA  136

9.4.2.1   Growing number of hospitals and healthcare policy reforms to drive growth              136

TABLE 126         CHINA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)          137

TABLE 127         CHINA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)          137

9.4.3      JAPAN  138

9.4.3.1   Strong healthcare system and rising geriatric population to support market growth              138

TABLE 128         JAPAN: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)          138

TABLE 129         JAPAN: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)          139

9.4.4      INDIA   139

9.4.4.1   Rising healthcare awareness and favorable government support to propel market growth   139

TABLE 130         INDIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)          140

TABLE 131         INDIA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)          140

9.4.5      AUSTRALIA       141

9.4.5.1   Rising prevalence of chronic diseases to drive market growth     141

TABLE 132         AUSTRALIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)          141

TABLE 133         AUSTRALIA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)          142

9.4.6      SOUTH KOREA 142

9.4.6.1   Growing number of cosmetic surgeries to drive demand for hemostats     142

TABLE 134         SURGICAL PROCEDURES IN SOUTH KOREA, 2021           142

TABLE 135         SOUTH KOREA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 143

TABLE 136         SOUTH KOREA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 143

9.4.7      SINGAPORE      143

9.4.7.1   Government initiatives to promote healthcare services to support market growth              143

TABLE 137         SINGAPORE: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)          144

TABLE 138         SINGAPORE: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)          144

9.4.8      NEW ZEALAND 145

9.4.8.1   Increasing number of hip fractures to propel market growth      145

TABLE 139         NEW ZEALAND: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 145

TABLE 140         NEW ZEALAND: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 146

9.4.9      INDONESIA       146

9.4.9.1   Lucrative growth opportunities for players to boost market        146

TABLE 141         INDONESIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)          147

TABLE 142         INDONESIA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)          147

9.4.10    MALAYSIA         147

9.4.10.1 Low healthcare costs, modern medical technology, and highly qualified doctors to favor market growth           147

TABLE 143         MALAYSIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)          148

TABLE 144         MALAYSIA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)          148

9.4.11    REST OF ASIA PACIFIC  149

TABLE 145         REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)     149

TABLE 146         REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)     150

9.5         LATIN AMERICA             150

TABLE 147         LATIN AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2018–2021 (USD MILLION)     151

TABLE 148         LATIN AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2022–2028 (USD MILLION)     151

TABLE 149         LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 151

TABLE 150         LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 152

TABLE 151         LATIN AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2018–2021 (USD MILLION)          152

TABLE 152         LATIN AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2022–2028 (USD MILLION)          152

TABLE 153         LATIN AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2018–2021 (USD MILLION)          153

TABLE 154         LATIN AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2022–2028 (USD MILLION)          153

9.5.1      LATIN AMERICA: RECESSION IMPACT   153

9.5.2      BRAZIL 154

9.5.2.1   Brazil to dominate Latin American market for hemostats           154

TABLE 155         BRAZIL: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)          154

TABLE 156         BRAZIL: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)          154

9.5.3      MEXICO             155

9.5.3.1   Low-cost surgeries to drive medical tourism in Mexico 155

TABLE 157         MEXICO: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)          155

TABLE 158         MEXICO: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)          156

9.5.4      REST OF LATIN AMERICA          156

TABLE 159         REST OF LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)          156

TABLE 160         REST OF LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)          157

9.6         MIDDLE EAST & AFRICA             157

9.6.1      STRENGTHENING OF HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH        157

TABLE 161         MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)     158

TABLE 162         MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)     158

TABLE 163         MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY FORMULATION, 2018–2021 (USD MILLION)        159

TABLE 164         MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY FORMULATION, 2022–2028 (USD MILLION)        159

TABLE 165         MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY APPLICATION, 2018–2021 (USD MILLION)           159

TABLE 166         MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY APPLICATION, 2022–2028 (USD MILLION)           160

9.6.2      MIDDLE EAST & AFRICA: RECESSION IMPACT   160

10          COMPETITIVE LANDSCAPE       161

10.1       OVERVIEW        161

10.2       KEY PLAYER STRATEGIES/RIGHT TO WIN          161

10.2.1    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HEMOSTATS MARKET            161

TABLE 167         OVERVIEW OF STRATEGIES DEPLOYED BY KEY HEMOSTAT MANUFACTURING COMPANIES             161

10.3       REVENUE ANALYSIS      163

FIGURE 28         REVENUE ANALYSIS OF TOP PLAYERS IN HEMOSTATS MARKET (2018–2022)     163

10.4       MARKET SHARE ANALYSIS         164

FIGURE 29         MARKET SHARE ANALYSIS OF TOP PLAYERS IN HEMOSTATS MARKET (2022) 164

TABLE 168         HEMOSTATS MARKET: DEGREE OF COMPETITION        164

10.5       COMPANY EVALUATION MATRIX          166

10.5.1    LIST OF EVALUATED VENDORS             166

10.5.2    STARS  166

10.5.3    EMERGING LEADERS    166

10.5.4    PERVASIVE PLAYERS     166

10.5.5    PARTICIPANTS 166

FIGURE 30         HEMOSTATS MARKET: COMPANY EVALUATION MATRIX (2022)   167

10.5.6    COMPANY FOOTPRINT 168

10.5.6.1 Product & regional footprint analysis             168

FIGURE 31         PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN HEMOSTATS MARKET        168

TABLE 169         HEMOSTATS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS   168

TABLE 170         COMPANY FOOTPRINT, BY TYPE           169

TABLE 171         COMPANY FOOTPRINT, BY REGION      169

10.6       START-UP/SME EVALUATION MATRIX 170

10.6.1    PROGRESSIVE COMPANIES       170

10.6.2    RESPONSIVE COMPANIES          170

10.6.3    DYNAMIC COMPANIES 170

10.6.4    STARTING BLOCKS       170

FIGURE 32         HEMOSTATS MARKET: START-UP/SME EVALUATION MATRIX (2022)   171

10.7       COMPETITIVE SCENARIO          172

10.7.1    PRODUCT LAUNCHES & APPROVALS    172

TABLE 172         KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2018–OCTOBER 2023)             172

10.7.2    DEALS  172

TABLE 173         KEY DEALS (JANUARY 2018–OCTOBER 2023)      172

10.7.3    OTHER KEY DEVELOPMENTS   173

TABLE 174         OTHER KEY DEVELOPMENTS (JANUARY 2018–OCTOBER 2023)              173

11          COMPANY PROFILES    174

(Business overview, Products offered, Recent developments & MnM View)*

11.1       KEY PLAYERS   174

11.1.1    JOHNSON & JOHNSON  174

TABLE 175         JOHNSON & JOHNSON: BUSINESS OVERVIEW    174

FIGURE 33         JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022)    175

11.1.2    BAXTER INTERNATIONAL         177

TABLE 176         BAXTER INTERNATIONAL: BUSINESS OVERVIEW           177

FIGURE 34         BAXTER INTERNATIONAL: COMPANY SNAPSHOT (2022)              178

11.1.3    PFIZER INC.       181

TABLE 177         PFIZER INC.: BUSINESS OVERVIEW        181

FIGURE 35         PFIZER INC.: COMPANY SNAPSHOT (2022)         182

11.1.4    B. BRAUN SE     184

TABLE 178         B. BRAUN SE: BUSINESS OVERVIEW       184

FIGURE 36         B. BRAUN SE: COMPANY SNAPSHOT (2022)        185

11.1.5    BECTON, DICKINSON AND COMPANY  187

TABLE 179         BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW              187

FIGURE 37         BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)   188

11.1.6    TELEFLEX INCORPORATED      190

TABLE 180         TELEFLEX INCORPORATED: BUSINESS OVERVIEW         190

FIGURE 38         TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2022)              191

11.1.7    MEDTRONIC PLC           194

TABLE 181         MEDTRONIC PLC: BUSINESS OVERVIEW             194

FIGURE 39         MEDTRONIC PLC: COMPANY SNAPSHOT (2022)             195

11.1.8    HEMOSTASIS, LLC         196

TABLE 182         HEMOSTASIS, LLC: BUSINESS OVERVIEW           196

11.1.9    STRYKER CORPORATION           198

TABLE 183         STRYKER CORPORATION: BUSINESS OVERVIEW             198

FIGURE 40         STRYKER CORPORATION: COMPANY SNAPSHOT (2022)              199

11.1.10  INTEGRA LIFESCIENCES            201

TABLE 184         INTEGRA LIFESCIENCES: BUSINESS OVERVIEW 201

FIGURE 41         INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2022) 202

11.1.11  ADVANCED MEDICAL SOLUTIONS GROUP PLC 203

TABLE 185         ADVANCED MEDICAL SOLUTIONS GROUP PLC: BUSINESS OVERVIEW        203

FIGURE 42         ADVANCED MEDICAL SOLUTIONS GROUP PLC: COMPANY SNAPSHOT (2022)          204

11.1.12  SAMYANG HOLDINGS CORPORATION  206

TABLE 186         SAMYANG CORPORATION: BUSINESS OVERVIEW           206

FIGURE 43         SAMYANG CORPORATION: COMPANY SNAPSHOT (2022)              206

*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.

11.2       OTHER PLAYERS           208

11.2.1    MARINE POLYMER TECHNOLOGIES, INC.           208

11.2.2    GELITA MEDICAL GMBH           208

11.2.3    DILON TECHNOLOGIES, INC.    209

11.2.4    BETATECH MEDICAL    209

11.2.5    MERIL LIFE SCIENCES PVT. LTD.            210

11.2.6    BIOCER ENTWICKLUNGS-GMBH            210

11.2.7    UNILENE           211

11.2.8    KATSAN MEDICAL DEVICES      211

11.2.9    TRICOL BIOMEDICAL   212

11.2.10  3-D MATRIX MEDICAL TECHNOLOGY   212

11.2.11  HEMOSTAT MEDICAL GMBH    213

11.2.12  MEDTRADE PRODUCTS LIMITED          213

11.2.13  ALTAYLAR MEDICAL    214

12          APPENDIX         215

12.1       KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL             219

12.2       CUSTOMIZATION OPTIONS      221

12.3       RELATED REPORTS       221

12.4       AUTHOR DETAILS         222